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In 2009, the United Nations estimated that 33.2 million people worldwide were living with human immunodeficiency virus type 1 (HIV-1) in-fection and that 2.6 million people had been newly infected.1 The need for ef-
fective HIV-1 prevention has never been greater. In this review, we address recent 
critical advances in our understanding of HIV-1 transmission and acute HIV-1 infec-
tion. Fourth-generation HIV-1 testing, now available worldwide,2,3 will allow the 
diagnosis of infection in many patients and may lead to new treatments and oppor-
tunities for prevention.
The HI V-1  Tr a nsmission E v en t
More than 80% of adults infected with HIV-1 became infected through the exposure 
of mucosal surfaces to the virus; most of the remaining 20% were infected by per-
cutaneous or intravenous inoculations.1 The risk of infection associated with differ-
ent exposure routes varies,4 but no matter what the transmission route, the timing of 
the appearance of viral and host markers of infection is generally uniform and fol-
lows an orderly pattern.5 Immediately after exposure and transmission, as HIV-1 is 
replicating in the mucosa, submucosa, and draining lymphoreticular tissues (Fig. 1),6,7 
the virus cannot be detected in plasma; this so-called eclipse phase generally lasts 
7 to 21 days.8,9 Once HIV-1 RNA reaches a concentration of 1 to 5 copies per milliliter 
in plasma, the virus can be detected with the use of sensitive qualitative methods 
of nucleic acid amplification10; at concentrations of 50 copies per milliliter, HIV-1 can 
be detected by means of quantitative clinical assays used to monitor viral load.11 
The stages that define acute and early HIV-1 infection are characterized by the se-
quential appearance of viral markers and antibodies in the blood (Fig. 2).5 More 
sensitive, fourth-generation tests, which detect both antigens and antibodies, shrink 
the virus-positive–antibody-negative window by about 5 days.12 Testing for viral 
RNA in plasma closes this gap by an additional 7 days.
The characteristic appearance in the blood of viral markers of acute HIV-1 infec-
tion belies an extremely complicated and still poorly understood series of virus–host 
cell interactions in the tissues (Fig. 1).4,13 Given the varied routes of viral transmis-
sion — cervicovaginal, penile, rectal, oral, percutaneous, intravenous, in utero — 
and the distinctly different histologic features of these tissues, it is not surprising 
that several cell types are candidates for early infection. More is known about vagi-
nal transmission than about other routes, and the study of human tissue explants14,15 
and the Indian rhesus macaque model of vaginal transmission of the simian im-
munodeficiency virus (SIV)13,16-18 have been informative (Fig. 1). The preponder-
ance of evidence implicates CD4 T cells and Langerhans’ cells as the first targets 
of the virus,14,15 but other dendritic cells may play an important accessory role.19 
However, recent observations of mucosally transmitted strains of HIV-1 reveal 
that monocyte-derived macrophages are generally 
poor targets for infection as compared with CD4 
T cells.20,21
Regardless of the route of viral transmission 
and the first cells infected, within a few days, 
viral replication converges on the lymphoreticu-
lar system of the gastrointestinal tract (i.e., gut-
associated lymphoid tissue).22-25 In this tissue, in 
both humans and macaques, the phenotype of 
most productively infected cells appears to be the 
resting CD4 T cell lacking activation markers and 
expressing low levels of the chemokine receptor 
CCR5.16-18 Many of these cells express α4β7 inte-
grin receptors and type 17 helper T (Th17)–cell 
surface markers.26,27 (Since these receptors are 
also detected on T cells harvested from the geni-
tal mucosa, they may play an important role in 
HIV acquisition.28) The rapid expansion of HIV-1, 
first in gut-associated lymphoid tissue and then 
systemically,25,29 along with a sharp rise in plas-
ma levels of viral RNA, is clinically important be-
cause of the coincident irreversible destruction of 
reservoirs of helper T cells and the establishment 
of viral latency (defined as the silent integration 
of HIV-1 DNA into the genomes of resting T cells, 
an effect that has stymied curative treatment ef-
forts30,31).
Rather than being genetically homogeneous, 
RNA viruses, including HIV-1, consist of complex 
mixtures of mutant and recombinant genomes 
called quasi-species. Genetic studies of the HIV-1 
quasi-species in patients with chronic infection 
as compared with patients with acute infection 
have brought some clarity to the qualitative and 
quantitative aspects of HIV-1 transmission.8 Fig-
ure 3 depicts the HIV-1 transmission event,8,9,32,33 
in which the inoculum (e.g., semen, cervicovagi-
nal secretions, or blood) contains a complex ge-
netic quasi-species of viruses, of which only a very 
small number are likely to broach mucosal bar-
riers and establish infection. Lee and colleagues9 
developed a model that allows transmitted viral 
genomes to be inferred from a phylogenetic 
analysis of the viral quasi-species that replicate 
in the weeks after infection. Empirical analyses 
based on single-genome amplification of HIV-1 
RNA in plasma or HIV-1 DNA in blood lympho-
cytes have provided robust evidence to support 
this model.8,20,21,33-38 A single virion is respon-
sible for HIV-1 transmission in approximately 
80% of heterosexuals but in only about 60% of 
men who have sex with men and about 40% of 
injection-drug users.8,20,21,33-35 In injection-drug 
users, as many as 16 transmitted virions have 
been found to be responsible for productive in-
fection,36 which would be consistent with the 
absence of a mucosal barrier to transmission. 
The phenotypes of cloned proviruses correspond-
ing to transmitted (or founder) viruses are nearly 
always CD4 and CCR5 T-cell tropic variants and 
exhibit neutralization-sensitivity patterns that are 
typical of primary viral strains. These phenotypic 
properties are present at the moment of trans-
mission, when the virus encounters the first tar-
get cell; they are not the consequence of viral ad-
aptation to the new host.8,20,21
Ini ti a l Innate Immune 
R esponses t o HI V-1
The first signal of an immune response to HIV-1 
infection is the appearance of acute-phase reac-
Figure 1 (facing page). Progression from HIV-1 
Transmission to Productive Clinical Infection.
HIV-1 must traverse several tissue layers in the female 
vagina or rectal mucosa to come into contact with ap-
propriate receptive cells (Panel A). The CCR5 (R5) viral 
strain has selective transmission advantages that re-
main poorly explained, and R5 variants make up the 
majority of transmitted and founder viruses. CXCR4 
(X4) variants are transmitted only rarely. Founder vi-
ruses come into contact with Langerhans’ cells or CD4 
T cells in squamous epithelium; CD4 T cells can also 
be infected by viruses bound to submucosal dendritic 
cells. It is not clear whether submucosal macrophages 
are an initial target, since most founder viruses poorly 
infect macrophages in vitro. The challenge for HIV-1 
transmission in the male genital tract differs somewhat 
from that in the vagina because of differences in anato-
my, but the penile foreskin and urethra harbor critical 
virus-receptive cells (Panel B). Virus–cell interactions 
in the male submucosa are likely to be similar to those 
in female submucosa, with viral targets including Lang-
erhans’ cells, other submucosal dendritic cells, and 
CD4 cells. Removal of the foreskin through elective cir-
cumcision can prevent at least 60% of HIV-1 infections 
in men.6 Although the time required for HIV-1 virions 
or virus-infected cells to traverse epithelial barriers is 
short (hours), it probably takes as long as 3 to 6 days 
for HIV-1 infection and propagation to occur and for 
the virus to spread beyond submucosal CD4 T cells 
(Panel C). Dissemination into draining lymph nodes 
and the systemic circulation rapidly follows, with es-
tablishment of the CD4 T-cell viral reservoirs. Studies 
in nonhuman primates of the timing of response to 
postexposure prophylaxis with antiretroviral drugs sug-
gests that the time to establishment of the CD4 T-cell 
reservoir may be as short as 24 hours.7
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tants, including alpha 1-antitrypsin and serum amy-
loid A, in plasma 3 to 5 days after transmission39
(Fig. 2). The steep rise in the HIV-1 viral load 
(ramp-up viremia) coincides with a large burst of 
inflammatory cytokines led by interferon-α and 
interleukin-1540 and a shower of plasma micropar-
ticles with surface phosphatidylserine, derived 
from infected and activated CD4 T cells undergo-
ing apoptosis; these particles have immunosup-
pressive properties.41
The earliest cytokines are produced by dendritic 
cells, but later in the infective process, multiple 
cell types (e.g., monocytes, macrophages, natural 
killer [NK] cells, and T cells) also produce these 
mediators.42 Although cytokines enhance protec-
tive antiviral immune responses in acute HIV-1 
infection, the cytokine storm probably also con-
tributes to harmful immune activation and loss 
of CD4 T cells.
NK cells are activated in acute HIV-1 infection 
and, in vitro, kill cells infected with the virus.43
NK cells have a range of receptors that either en-
hance or inhibit their function. NK-cell immu-
noglobulin-like receptors interact with HLA mol-
ecules with some specificity for the peptides they 
bind.44 This activity might explain the genetic as-
sociations between certain NK-cell immunoglob-
ulin-like receptors and HLA types with more fa-
vorable outcomes of infection.45
A da p ti v e Immune R esponses 
in Acu te HI V-1  Infec tion
The initial antibody response to the viral enve-
lope is non-neutralizing and does not select for 
viral escape46 (Fig. 2). Antibodies that neutralize 
the transmitted founder virus are not detected 
until 3 months or more after infection.47 Although 
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Figure 2. Natural History and Immunopathogenesis of HIV-1 Infection.
The progression of HIV-1 infection can be depicted as six discrete stages7 (indicated by Roman numerals). These stag-
es are defined according to the results of standard clinical laboratory tests (listed above the curve for viral load). The 
stages are based on the sequential appearance in plasma of HIV-1 viral RNA; the gag p24 protein antigen; antibodies 
specific for recombinant HIV-1 proteins, detected with the use of an enzyme-linked immunosorbent assay (ELISA); and 
antibodies that bind to fixed viral proteins, including p31, detected on Western immunoblot. A plus sign indicates a 
positive test result, a minus sign a negative result, and a plus–minus sign a borderline-positive result. The lines below 
the viral-load curve show the timing of key events and immune responses that cannot be measured with standard clini-
cal laboratory assays, beginning with the establishment of viral latency. Acute-phase reactants include elevated levels 
of serum amyloid protein A. CD8 T-cell responses lead to the appearance of escape mutants concurrently with inflam-
matory cytokines in plasma. Immune complexes of antibodies with viral proteins, such as the HIV-1 envelope glycopro-
tein (gp41), precede the first appearance of free antibodies to gp41. Strain-specific antibodies to gp41 that neutralize 
the virus do not appear until sometime close to day 80. The portion of the line for viral latency that is dotted reflects 
uncertainty as to exactly when latency is first established; the dotted line for acute-phase reactants indicates that not 
all patients have elevated levels of reactants at this early point in the process of infection; the gray segment of the black 
line for viral load reflects the inability to measure very low viral loads.
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Figure 3. Model of HIV-1 Transmission.
A genetically and phenotypically diverse quasi-species of virus is present in the semen, cervicovaginal secretions, or 
blood of persons with chronic HIV-1 infection, but most often, only a single virion or virally infected cell is transmit-
ted and leads to productive clinical infection. Other viruses may breach the mucosal or cutaneous surfaces, but they 
generally do not result in productive infection or contribute to it, presumably because such viruses are defective or 
less fit or simply fail to come into contact with susceptible target cells. R0 represents the basic reproductive ratio, 
which corresponds to the number of secondary infections caused by one infected cell. If this number falls below 1, 
infection is extinguished. In acute infection, the number of productively infected cells and the concentration of free 
virus in the plasma increase exponentially, with an estimated R0 of 8.32
many of the targets of neutralizing antibodies are 
on the glycoprotein-120 component of the HIV-1 
envelope, the initial antibody response to HIV-1 
is focused on non-neutralizing sites of the glyco-
protein 41 envelope stalk.46 It is not known why 
the initial HIV-1 antibody response is directed (or 
misdirected) to ineffective envelope sites, but the 
response may be related in part to the relative 
abundance of non-native HIV-1 envelope mole-
cules when glycoprotein 41 is exposed, whereas 
the exposure of functional native envelope trimers 
is rare.48 Similarly, other potentially protective an-
tibodies directed against envelope proteins, such 
as antibodies that neutralize the founder viral 
strain or those that mediate antibody-dependent 
cellular cytotoxicity, do not arise until weeks af-
ter transmission.47,49,50 By the time a potentially 
effective antibody response has developed, it is 
much too late to influence the course of the in-
fection (Fig. 2).
The first CD8 T-cell responses appear days be-
fore the peak of viremia and focus on between 
one and three distinct epitopes (short antigenic 
peptides bound to HLA molecules that are de-
rived from HIV-1 proteins) most commonly found 
in HIV-1 proteins nef and gag.51 These first T-cell 
responses select escape mutants (which cannot be 
recognized by killer CD8 T cells), with complete 
replacement of the original viral amino acid se-
quence by the new sequence in 10 to 21 days.52 
These initial T-cell responses are followed by new 
T-cell responses to other epitopes, which often
escape as well. A combination of strong T-cell
responses, producing chemokine (C-C motif) li-
gand 4 (CCL4), and a focus on epitopes with high
levels of variability (entropy) favors rapid escape.53
These CD8 T cells also express perforin — a pro-
tein closely associated with cell-mediated cyto-
toxicity — which suggests that they can kill in-
fected cells.54
Other CD8 T-cell responses do not appear to 
select escape mutants — or must do so very 
slowly. Some of these T cells may be functionally 
deficient, but most appear to be effective, focus-
ing on regions of the virus that can mutate, but 
at the cost of making the virus less efficient in 
replication.55 These latter T cells are likely to con-
tribute to the control of HIV-1. As this T-cell re-
sponse evolves, the plasma viral load falls (Fig. 2). 
The rate of loss of virus containing the epitopes 
recognized by the early T-cell responses that drive 
escape provides a measure of the rate of killing 
(or removal) of virus-infected cells in vivo.52 Other 
factors, such as loss of susceptible cells (given the 
extreme depletion of activated CD4 T cells in gut-
associated lymphoid tissue), probably also play a 
part in lowering the initial peak viral load.23,56
During acute HIV-1 infection, irrevocable de-
pletion of CD4 T lymphocytes from the gastro-
intestinal tract23 and some other lymphoid tissues 
has been observed in humans and rhesus ma-
caques.25 In humans, adjunctive damage to the 
mucosal barriers may allow leakage of gut bacte-
rial products into otherwise sterile tissues and 
to the bloodstream, leading to further immune 
activation that can promote HIV replication and 
have other adverse consequences.57 The rapid, 
early, and massive loss of CD4 T cells in lymphoid 
organs (which is poorly reflected in CD4 T-cell 
counts in blood) probably accounts for the weak 
CD4 T-cell responses in cases of acute HIV-1 in-
fection.
The importance of CD8 T cells in controlling 
acute HIV-1 infection is consistent with studies 
in the rhesus macaque SIV model showing that 
in vivo depletion of CD8 T cells abrogated viral 
control in both acute infection and chronic in-
fection.58 In addition, many studies in macaques 
have shown that vaccines that stimulate SIV-spe-
cific CD8 T-cell responses can attenuate subse-
quent SIV infection.59 These data are also consis-
tent with extensive work showing that in patients 
with certain HLA types, particularly HLA-B57 (and 
the very closely related HLA-B58) and HLA-B27, 
viral control is often better than average, with a 
lower virus set point and longer survival in the 
absence of antiretroviral therapy.60 The B27, B57, 
and B58 molecules present highly conserved parts 
of the virus to T cells, so that the virus can es-
cape immune control only at the cost of replica-
tive fitness.55
De tec tion of Acu te HI V-1 
Infec tion
In the absence of a high degree of clinical suspi-
cion, the symptoms associated with acute HIV-1 
infection are often too vague or nonspecific to 
lead to a diagnosis.61 In the absence of antibody 
seroconversion, confirmation of acute infection 
requires detection of HIV-1 RNA or p24 antigen, 
but tests designed for this purpose have hereto-
fore not been routinely available. In public health 
settings, a cross-sectional screening strategy that 
involves searching for HIV RNA in pooled, anti-
body-negative samples has been used to increase 
detection.61 This approach has been used to de-
tect acute HIV-1 infection, with a prevalence of 0.5 
cases detected per 1000 persons tested, in North 
Carolina, to 4.0 cases per 1000, in San Francisco; 
acute infection accounted for 5 to 10% of all cas-
es of HIV in both places.
As an alternative and more practical strategy, 
an enzyme-linked immunosorbent assay that can 
concomitantly detect viral p24 antigen and anti-
viral antibodies has been developed and approved 
for clinical use.2,3,61 This test can increase the 
number of patients with acute HIV-1 infection 
whose condition is diagnosed at a time when they 
are most infectious to others.3 It is anticipated 
that a rapid point-of-care test will also be devel-
oped for the purpose of detecting acute HIV-1 
infection. The implementation of these tests across 
the United States in public health and commer-
cial laboratories can be expected to dramatically 
increase the number of patients with acute HIV-1 
infection who will require care.
Public He a lth Consequences 
of Acu te HI V-1  Infec tion
The per-person probability of transmitting HIV-1 
is most closely correlated with the viral burden in 
blood; each time the viral burden in an HIV-1–
infected person increases by a factor of 10, the 
risk of transmission is expected to increase by a 
factor of 2.5.62 The risk of contagion from pa-
tients with acute, early infection appears to be 
much higher than that from patients with estab-
lished infection,63 at least in part because of the 
high viral load and the homogeneity of viral vari-
ants clearly capable of causing infection. In the 
rhesus macaque SIV model, plasma from animals 
with acute infection is up to 750 times as infec-
tious, on a per-virion basis, as plasma from ani-
mals with chronic infection.64 The reduced risk 
of contagion from patients with chronic infection 
probably results from the presence of neutraliz-
ing antibodies, which are not evident in acute in-
fection.
Mathematical models used to estimate the role 
of patients with acute infection in the spread of 
HIV-1 have produced strikingly different results, 
depending on the population studied and the as-
sumptions used (Fig. 4).65-77 The epidemic phase 
used for modeling has been a critical determi-
nant.78 In communities subject to a new epidemic, 
early infections are held to be responsible for a 
considerable share of HIV-1 transmission, since a 
larger proportion of infected persons have acute 
or early-stage disease rather than late-stage dis-
ease.79 Sexual behavior plays an important role 
in rates of infection, with high rates of partner 
change increasing the chances of contact with a 
person who has acute HIV-1 infection. In a recent 
comprehensive study conducted in Lilongwe, Ma-
lawi, in which both behavioral and biologic data 
were used, 38% of cases of HIV-1 were ascribed to 
sexual exposure to patients in the first 5 months 
of infection, even though there is a long-estab-
lished epidemic in Malawi.75 The results of the 
Malawi study may be most relevant to the HIV-1 
pandemic in sub-Saharan Africa.
The importance of acute HIV-1 infection can 
also be seen in studies of phylogenetically related 
cases, such as the study reported by Brenner and 
colleagues.79 They state that more than half the 
patients with newly diagnosed early HIV-1 infec-
tion in Montreal are infected with viral variants 
that can be linked through phylogenetic studies, 
which suggests the presence of clusters of trans-
mission, perhaps from patients with acute and 
early infection.
Pr e v en ting HI V-1  Infec tion
Effective HIV preventive strategies must be in 
place before or immediately after the transmis-
sion event. This is a tall order for antiviral prophy-
laxis, administered before or after exposure, or a 
vaccine. Indeed, the antibody responses directed 
against the HIV-1 envelope after the administra-
tion of vaccine regimens are not of long dura-
tion.80,81 Nevertheless, there are several points in 
the transmission event at which the founder virus 
may be vulnerable to inhibition by antibodies, 
ranging from the entry of virus or virus-infected 
cells into mucus in the genital tract to cell-to-cell 
transmission in genital tract submucosa (Fig. 1).82 
Weakly neutralizing antibodies that mediate an-
tibody-dependent, cell-mediated cytotoxicity or 
antibody-dependent cellular viral inhibition may 
have a protective effect by stimulating immune 
cells to produce anti–HIV-1 chemokines, such as 
CCL3, CCL4, and CCL5.81 In a recent vaccine effi-
cacy trial conducted in Thailand, the partial pre-
vention of HIV-1 acquisition observed may have 
been due to a transient antibody response83; the 
results could also be explained by the actions of one 
or more innate antiviral immune mechanisms.
An alternative prevention strategy that is more 
readily available is that of offering antiretroviral 
agents to people at risk before or immediately 
after HIV exposure or as a means of secondary 
prevention.84,85 Use of the antiretroviral drug 
tenofovir as a topical prophylactic agent before 
viral exposure in women at high risk led to a 39% 
reduction in incident cases of HIV infection that 
was directly correlated with concentrations of the 
drug in mucosal tissue.86 Seven ongoing trials of 
oral preexposure prophylaxis have been under-
taken.87 A multinational trial focused on men 
who have sex with men87 showed that a once-
daily pill containing tenofovir plus emtricitabine 
provided an average of 44% protection over and 
above that conferred by the provision of compre-
hensive preventive services, including the provision 
of condoms and counseling.88 The level of protec-
tion varied widely, depending on how consis-
tently participants used preexposure prophylaxis. 
The Centers for Disease Control and Prevention 
has issued preliminary recommendations for the 
use of preexposure prophylaxis by men who have 
sex with men.89 Work with rhesus macaques 
suggests that achieving high levels of antiviral 
agents in mucosal tissues shortly after exposure 
to SIV–HIV viral chimeras is critical for protection 
from infection.90 This work, along with the further 
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Figure 4. Role of Acute and Early HIV-1 Infection in the Spread of HIV-1, According to Population Studies in Sub-Saharan Africa, 
the United States, and Europe.
Acute and early HIV-1 infection is responsible for secondary transmission of HIV-1, which is critical to the epidemic spread of the virus. 
A variety of models65-77 have generated widely varying estimates of the potential importance of acute and early HIV-1 infection, depend-
ing on the patient populations studied and the assumptions of the models. These models generally include people in whom the virus 
was detected before and during seroconversion (acute HIV-1 infection) and for several weeks thereafter (early infection) (see Hayes and 
White73 and Salomon and Hogan76). The estimates reflect the proportion of all transmissions during an individual patient’s entire infec-
tious period. The extent to which this proportion corresponds to the proportion of all transmissions that occur during acute and early 
HIV-1 infection at the population level depends on the epidemic phase and the distribution of patterns of sexual contact in the popula-
tion (see Pinkerton and Abramson77, Kretzschmar and Dietz,70 and Koopman et al.69). Transmission probabilities were drawn from the 
population category shown, but the reported estimates result from a range of hypothetical sexual-behavior variables that do not neces-
sarily reflect a specific population (see Kretzschmar and Dietz70 and Abu-Raddad and Longini74). The range of estimates shown was ex-
tracted from the endemic-phase portion of graphs showing the proportion of new infections resulting from early HIV-1 infection over 
calendar time. I bars represent an estimate of the percentage of new HIV cases caused by people with acute or early HIV infection. 
MSM denotes men who have sex with men.
exploration of new drug combinations, will prob-
ably play a role in the further development of pre-
exposure and postexposure prophylaxis.
M a naging Acu te HI V-1  Infec tion
The health care provider has three responsibili-
ties with respect to acute HIV-1 infection: detec-
tion; secondary prevention, which in some cases 
must include partner notification (and possibly 
postexposure prophylaxis with antiretroviral ther-
apy); and initiation of antiretroviral therapy, if it 
is considered appropriate. Although the fourth-
generation HIV tests have the capacity to detect 
acute HIV-1 infection, algorithms that will reduce 
the time to diagnosis and linkage to medical care 
must be put into place.3 Equally important, strat-
egies must be developed to offer the best possible 
counseling in order to reduce further spread of 
HIV-1 and to break up the sexual networks that 
can form around patients with acute HIV-1 infec-
tion.91 However, partner notification in the Unit-
ed States has been limited92 and is only now be-
ing studied in resource-constrained countries.93 
A recent study in Africa has highlighted the dif-
ficulty of explaining acute HIV-1 infection to study 
subjects in a manner that is likely to reduce fur-
ther transmission.94
Alternatively, antiretroviral therapy could be 
used to suppress viral replication in order to re-
duce HIV-1 transmission. What constitutes the 
optimal use of antiretroviral therapy for patients 
with acute infection is unclear, in part because 
the extent of the personal health benefit derived 
from early use of antiretroviral therapy remains 
in question.95,96 There have been considerable dif-
ferences in reported results of the clinical bene-
fits of antiretroviral therapy for patients with 
primary HIV infection because in many cases 
antiretroviral therapy was initiated weeks or 
even months after HIV-1 acquisition — probably 
much too late to influence the course of dis-
ease. A few small studies have shown some bene-
fit when therapy was provided before or during 
seroconversion, with some degree of immune 
preservation96 and with sustained reduction of 
blood viral load after antiretroviral therapy was 
discontinued. Moir et al. reported that patients 
treated soon after receiving the diagnosis had im-
proved B-cell function.97 Very early administra-
tion of antiretroviral therapy may limit the size of 
the latent pool of HIV-1–infected CD4 T cells.98,99 
Although encouraging, these results underscore 
the need for well-constructed clinical trials that 
will provide the basis for determining the over-
all cost–benefit ratio of antiretroviral therapy for 
acute HIV-1 infection and for balancing the pub-
lic health benefits with the benefits for individ-
ual patients.
In the most recent treatment guidelines from 
the International Antiviral Society — USA, the 
authors argue that potential benefits to public 
and individual health may even now justify the 
treatment of patients with acute HIV infection, 
particularly those who are symptomatic.100 The 
authors of other guidelines have come to similar 
conclusions, setting the stage for regular treat-
ment of persons with acute HIV infection. If anti-
retroviral therapy is to be provided, the treatment 
regimen might include drugs that concentrate in 
the genital tract of men and women85 and an 
integrase inhibitor, the latter because of the ra-
pidity with which this class of drugs lowers the 
viral load.101 Some pilot studies using multidrug 
regimens, such as those administered before HIV 
seroconversion, are in progress.102
Conclusions
The earliest events in acute HIV-1 infection deter-
mine the future health of the individual patient 
and the extent of transmission in the general pop-
ulation. Recent studies have unraveled many of the 
initial immune events of acute infection. With im-
proved diagnostic tests, greater numbers of per-
sons with acute HIV-1 infection will come to the 
attention of practicing physicians and public 
health officials. Although considerable progress 
has been made in understanding the HIV-1 trans-
mission event, more studies are needed to develop 
optimal treatment and prevention strategies for 
people in the earliest stages of HIV-1 infection.
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